4D pharma PLC Sponsored ADR LBPS

Market cap
$37.2M
P/E
0.0×
Growth Flags show if company had growth for consecutive years
Older periods Dec '20 Feb '21 Jun '21 Dec '21
ROE

+8 more TTM periods

(215.05%) (154.94%) (453.64%) (742.15%)
ROA
(103.16%) (122.50%) (337.92%) (371.23%)
ROIC
(79.48%) (157.32%) 0.00% 0.00%
Return on Tangible Assets
(271.46%) (346.09%) (368.00%) (413.04%)
Average Days of Receivables
0.00 0.00 3,415.75 2,646.62
Free Cash Flow per Share
(3.13) 0.00 (0.45) (0.49)
Free Cash Flow
(44.61) (55.93) (71.38) (88.99)
Capital Expenditures
— (1.67) (1.21) —
Piotroski F-Score
4.00 3.00 1.00 1.00
Other line items
Cash ROIC
(85.69%) (104.23%) (81.83%) (135.43%)
Accounts Receivable Turnover
0.00 0.00 0.14 0.12
Accounts Payable Turnover
0.00 0.00 0.00 0.00
Inventory Turnover
0.00 — 0.00 0.00
Average Days of Payables
0.00 0.00 0.00 0.00
Days of Inventory on Hand
0.00 — 0.00 0.00
Tax Rate
(0.25) 0.00 (0.09) (0.08)
Research and Development Expense of Revenue
0.00% — 4,822.91% 3,879.85%
Selling, General and Administrative Expense of Revenue
0.00% — 1,285.44% 1,414.74%
Share Based Compensation of Revenue
— 0.00% 4,848.08% 0.00%
Interest Coverage
0.00 0.00 — —
Operating CF/Net income
0.94 0.90 0.51 0.66
Depreciation/Fixed assets
1.11 1.09 0.83 0.93
Capex/Depreciation
0.00 (0.30) (0.26) 0.00
Revenue per Share
0.00 — 0.01 0.01
Operating CF per Share
(3.13) 0.00 (0.44) (0.49)
Capex per Share
0.00 0.00 (0.01) 0.00
Capex to Sales
— 0.00 0.94 0.00
Net Profit Margin
0.00% 0.00% (10,604.48%) (9,577.06%)

Fold the line items

Columns are period end dates